Literature DB >> 8924899

Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma.

D S Wang1, Y Ueno, H Oyamada, S Kojima.   

Abstract

The effect of gamma-ray irradiation and camptothecin (CAM) on human colorectal adenocarcinoma (LS 174T) growth was examined. On inhibition of DNA synthesis of LS 174T cells, almost all combined treatments presented a synergistic effect, excepting that the additive effects were shown at the lowest or the highest doses of CAM prior to the gamma-ray (137Cs) irradiation. The in vivo antitumor activity of 131I-NCC-CO-411 monoclonal antibody against carcinoembryonic antigen in combination with CAM was assessed by a tumor growth rate in LS 174T tumor-bearing nude mice. The tumor growth of the combined group was supra-additively suppressed in comparison with that of the individual group. The results suggest that the efficacy of radioimmunotherapy may be enhanced by combination treatment with CAM. A clinical protocol involving a combination treatment with CAM is underway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8924899     DOI: 10.1248/bpb.19.354

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  3 in total

1.  Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice.

Authors:  Chia-Yuan Liu; Hui-Fen Liao; Tsang-En Wang; Shee-Chan Lin; Shou-Chuan Shih; Wen-Hsuing Chang; Yuh-Cheng Yang; Ching-Chung Lin; Yu-Jen Chen
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

2.  Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

Authors:  Michael B Tomblyn; Bryan H Goldman; Charles R Thomas; Jacqueline K Benedetti; Heinz-Josef Lenz; Vivek Mehta; Thaddeus Beeker; Philip J Gold; James L Abbruzzese; Charles D Blanke
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

3.  A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.

Authors:  R Glynne-Jones; S Falk; T S Maughan; H M Meadows; D Sebag-Montefiore
Journal:  Br J Cancer       Date:  2007-01-30       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.